A phase II trial of BMS-986419
Latest Information Update: 10 Jan 2024
Price :
$35 *
At a glance
- Drugs BMS-986419 (Primary)
- Indications Neurodegenerative disorders
- Focus Therapeutic Use
- 10 Jan 2024 New trial record
- 08 Jan 2024 According to a Evotec SE media release, the company expect to commence this study in 2024.